• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·MRK
Held by 3 Gurus
Share

Merck & Co., Inc. Stocks

$ 147.19Last Updated 11.11.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

$ 364.98B

$ 147.19
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.1%

Change

-0.11%

Fund

CITADEL ADVISORS LLC

Steven Cohen

Portfolio Weight (%)

0.1%

Change

-0.10%

Fund

Point72 Asset Management, L.P.

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.02%

Fund

Bridgewater Associates

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.1%-0.11%
Steven CohenPoint72 Asset Management, L.P.0.1%-0.10%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.02%

Latest news

06.11.2026 21:48

Moderna surges 700% on cancer vaccine hopes. Covid still drives 3Q revenue.

23.10.2026 00:09

Moderna plunges 25% as leaked cancer vaccine data falls short of lofty expectations

19.10.2026 18:09

Goldman names 23 'unloved' defensive stocks as tech falters

16.10.2026 08:00

Pharmaceutical companies benefited from the sell-off in the AI sector. Which stocks are nearing their all-time highs?

12.10.2026 15:36

Morning in New York: Oil Caught Between De-escalation and the Risk of New Attacks

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of MRK is 171 and suggests 16.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.11.2026 11:08

"No One Is Irreplaceable": What Major Investors Are Saying About Nvidia Without Huang

13.11.2026 09:00

Nvidia has promised to invest $10 billion in Anthropic. Will Huang's departure derail the record-breaking IPO?

13.11.2026 08:00

Burry Increased His Bets Against the Nasdaq 100 and Chipmakers Following the Resignation of Nvidia's CEO

13.11.2026 03:33

Shares of Nvidia's competitor soared 16% on the back of strong revenue. Is it too late to buy?

13.11.2026 02:42

"A Golden Opportunity": Who Came Out Ahead on the Day Stocks Plummeted Following Huang's Resignation

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026